Bio-Gene Technology Ltd - Asset Resilience Ratio

Latest as of December 2025: 20.35%

Bio-Gene Technology Ltd (BGT) has an Asset Resilience Ratio of 20.35% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

AU$300.00K

≈ $212.27K USD Cash + Short-term Investments

Total Assets

AU$1.47 Million

≈ $1.04 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Bio-Gene Technology Ltd's Asset Resilience Ratio has changed over time. Check Bio-Gene Technology Ltd (BGT) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Bio-Gene Technology Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BGT market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$0.00	0%
Short-term Investments	AU$300.00K	20.35%
Total Liquid Assets	AU$300.00K	20.35%

Asset Resilience Insights

Good Liquidity Position: Bio-Gene Technology Ltd maintains a healthy 20.35% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Bio-Gene Technology Ltd Industry Peers by Asset Resilience Ratio

Compare Bio-Gene Technology Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Sk Biopharmaceuticals Co Ltd KO:326030	Biotechnology	0.14%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	57.90%
TELIX Pharmaceuticals Ltd AU:TLX	Biotechnology	32.29%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Hangzhou Biotest Biotech Co Ltd SHG:688767	Biotechnology	0.56%
Theravance Biopharma Inc F:0TB	Biotechnology	37.29%

Annual Asset Resilience Ratio for Bio-Gene Technology Ltd (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Bio-Gene Technology Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-06-30	23.26%	AU$500.00K ≈ $353.78K	AU$2.15 Million ≈ $1.52 Million	-24.22pp
2024-06-30	47.47%	AU$1.50 Million ≈ $1.06 Million	AU$3.16 Million ≈ $2.24 Million	+46.46pp
2022-06-30	1.02%	AU$74.20K ≈ $52.50K	AU$7.30 Million ≈ $5.17 Million	-77.64pp
2021-06-30	78.65%	AU$3.93 Million ≈ $2.78 Million	AU$5.00 Million ≈ $3.54 Million	-4.82pp
2018-06-30	83.48%	AU$6.40 Million ≈ $4.53 Million	AU$7.67 Million ≈ $5.42 Million	+62.30pp
2017-06-30	21.17%	AU$2.00 Million ≈ $1.42 Million	AU$9.45 Million ≈ $6.68 Million	--

pp = percentage points

About Bio-Gene Technology Ltd

AU:BGT Australia Biotechnology

Market Cap

$4.75 Million

AU$6.71 Million AUD

Market Cap Rank

#28649 Global

#1535 in Australia

Share Price

AU$0.02

Change (1 day)

-4.35%

52-Week Range

AU$0.02 - AU$0.04

All Time High

AU$0.34